miRNA-195 exerts its anti-cancer effect against breast cancer by targeting fatty-acid synthase (FASN), 3-hydroxyl 3-methyl glutaryl CoA reductase (HMGCR), acetyl-CoA carboxylase (ACACA), and insulin receptor substrate-1 (IRS1), inhibiting the proliferation, invasion, angiogenesis, and metastasis of breast cancer cells (13,14). The gene discussed is FASN; the disease is breast cancer.